Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 10
1977 9
1978 4
1979 14
1980 13
1981 11
1982 27
1983 34
1984 47
1985 34
1986 40
1987 35
1988 25
1989 42
1990 55
1991 63
1992 55
1993 51
1994 61
1995 36
1996 34
1997 49
1998 37
1999 25
2000 34
2001 39
2002 38
2003 41
2004 27
2005 27
2006 31
2007 29
2008 27
2009 21
2010 24
2011 25
2012 22
2013 14
2014 15
2015 15
2016 12
2017 19
2018 17
2019 18
2020 17
2021 26
2022 12
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,310 results
Results by year
Filters applied: . Clear all
Page 1
The Synthesis of Nano-Doxorubicin and its Anticancer Effect.
Zhu L, Lin M. Zhu L, et al. Anticancer Agents Med Chem. 2021;21(18):2466-2477. doi: 10.2174/1871520621666201229115612. Anticancer Agents Med Chem. 2021. PMID: 33372884 Review.
Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due to the lack of tumor specificity of the drug and severe side effects such as myelosuppression, nephrotoxicity, dose-dependent cardio …
Doxorubicin (DOX) is widely used as a clinical first-line anti-cancer drug. However, its clinical application is severely limited due …
Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A, Shmeeda H, Barenholz Y. Gabizon A, et al. Clin Pharmacokinet. 2003;42(5):419-36. doi: 10.2165/00003088-200342050-00002. Clin Pharmacokinet. 2003. PMID: 12739982 Review.
Clinical studies of pegylated liposomal doxorubicin in humans have included patients with AIDS-related Kaposi's sarcoma (ARKS) and with a variety of solid tumours, including ovarian, breast and prostate carcinomas. ...There is evidence of selective tumour uptake in …
Clinical studies of pegylated liposomal doxorubicin in humans have included patients with AIDS-related Kaposi's sarcoma (ARKS) …
Clinical pharmacokinetics of doxorubicin.
Speth PA, van Hoesel QG, Haanen C. Speth PA, et al. Clin Pharmacokinet. 1988 Jul;15(1):15-31. doi: 10.2165/00003088-198815010-00002. Clin Pharmacokinet. 1988. PMID: 3042244 Review.
Doxorubicin (adriamycin) has a very wide antitumour spectrum, compared with other anticancer drugs; however, except for Hodgkin's disease, it is not associated with curative chemotherapy. ...Doxorubicin has been administered as frequent (weekly) low doses, si …
Doxorubicin (adriamycin) has a very wide antitumour spectrum, compared with other anticancer drugs; however, except for Hodgkin's …
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. O'Brien ME, et al. Ann Oncol. 2004 Mar;15(3):440-9. doi: 10.1093/annonc/mdh097. Ann Oncol. 2004. PMID: 14998846 Free article. Clinical Trial.
Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001). Overall survival was similar (21 and 22 months for PLD and doxorubicin, respectively; HR=0.94; 95%CI 0.74-1.19). ...CONCLUSIONS: In first-line t …
Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001). Overall sur …
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Judson I, et al. Eur J Cancer. 2001 May;37(7):870-7. doi: 10.1016/s0959-8049(01)00050-8. Eur J Cancer. 2001. PMID: 11313175 Clinical Trial.
CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types. ...Primary disease sites were well matched. CAELYX was significantly less myelosuppressive, only 3 (6%) …
CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubic …
Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
Zhang J, Jiang H, Zhang J, Bao G, Zhang G, Wang H, Wang X. Zhang J, et al. BMC Cancer. 2021 Dec 6;21(1):1301. doi: 10.1186/s12885-021-09050-6. BMC Cancer. 2021. PMID: 34872507 Free PMC article.
BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but significantly lower cardiotoxicity than conventional anthracycline. ...The lower limit of the 95% CI was - 5.0% > - 10.0%, suggesting tha …
BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin with comparable effectiveness but …
A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis.
Chen T, Shen HM, Deng ZY, Yang ZZ, Zhao RL, Wang L, Feng ZP, Liu C, Li WH, Liu ZJ. Chen T, et al. Mol Med Rep. 2017 Apr;15(4):2057-2066. doi: 10.3892/mmr.2017.6272. Epub 2017 Mar 1. Mol Med Rep. 2017. PMID: 28260045 Free PMC article.
Doxorubicin (DOX) is an antineoplastic drug widely used for the treatment of various types of cancer; however, it can induce severe side effects, such as myelosuppression and cardiotoxicity. ...The present study indicated that SYKT may counteract DOX-induced myel …
Doxorubicin (DOX) is an antineoplastic drug widely used for the treatment of various types of cancer; however, it can induce severe s …
Peptide-Based Hydrogels and Nanogels for Delivery of Doxorubicin.
Gallo E, Diaferia C, Rosa E, Smaldone G, Morelli G, Accardo A. Gallo E, et al. Int J Nanomedicine. 2021 Mar 1;16:1617-1630. doi: 10.2147/IJN.S296272. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33688182 Free PMC article.
INTRODUCTION: The clinical use of the antitumoral drug doxorubicin (Dox) is reduced by its dose-limiting toxicity, related to cardiotoxic side effects and myelosuppression. ...
INTRODUCTION: The clinical use of the antitumoral drug doxorubicin (Dox) is reduced by its dose-limiting toxicity, related to cardiot …
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
Wen XZ, Pan QZ, Xu BS, Xiao W, Weng DS, Zhao JJ, Xu HR, Huang Z, Niu XH, Zhang X. Wen XZ, et al. Cancer Chemother Pharmacol. 2022 Feb;89(2):209-215. doi: 10.1007/s00280-021-04371-6. Epub 2022 Jan 13. Cancer Chemother Pharmacol. 2022. PMID: 35022817 Clinical Trial.
PURPOSE: The repeated use of doxorubicin is limited due to dose-limiting cardiac toxicity. Pegylated liposomal doxorubicin (PEG-LD, Duomeisu) has a reduced cardiac toxicity. ...The main adverse event (AE) was myelosuppression. The most common non-hematologica …
PURPOSE: The repeated use of doxorubicin is limited due to dose-limiting cardiac toxicity. Pegylated liposomal doxorubicin (PE …
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF, Thougaard AV, Sehested M, Jensen PB. Hofland KF, et al. Clin Cancer Res. 2005 May 15;11(10):3915-24. doi: 10.1158/1078-0432.CCR-04-2343. Clin Cancer Res. 2005. PMID: 15897593
PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. ...RESULTS: Nontoxic dose …
PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs …
1,310 results